The stock's fall snapped an eight-day winning streak.

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...